In September 2024, we expanded the flexibility of our oral solid dose (OSD) early development research capabilities and pilot-scale manufacturing space.
Introducing a new, pilot-scale high-shear granulation and fluid bed (Glatt 10) processing suite (launched in mid-2024), along with two innovative offerings: The accelerated stability assessment program (ASAP) and compaction simulation (STYL’One Evo).
Led by a team of over a dozen scientists and engineers with extensive drug substance and drug product development experience and expertise.
With the support of over 800 talented employees, Thermo Fisher Scientific’s oral solid dose (OSD) site in Cincinnati, Ohio offers a range of drug development and commercial manufacturing services, including capabilities for:
By integrating scalable and flexible drug development and commercial manufacturing under one roof, this site enables biotech and pharma companies to “start here and stay here” throughout the entire lifecycle of their molecule.
Our Cincinnati site handles Cat 2 APIs and offers select suites for Cat 3 APIs. The specialized capabilities listed below are supported by our expertly resourced and well-equipped GMP laboratory space:
Over the past five years, our Cincinnati facility has successfully passed 22 regulatory inspections from 12 different health authorities, including 10 from the US FDA. This strong performance highlights our dedication to maintaining high operational standards.
To learn more about our equipment and capabilities, download our fact sheet.
2110 East Galbraith Road
Cincinnati, OH 45237-1625
Phone: +1 513 948 9111